{
    "SPADE_UN_13522": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_13522",
            "Peptide Name": "IPB02(SARS-CoV-2-S (1169-1203)-K)",
            "Source": "Synthetic construct",
            "Family": "Belongs to the betacoronaviruses spike protein family.",
            "Gene": "S",
            "Sequence": "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK",
            "Sequence Length": 36,
            "UniProt Entry": [
                "http://www.uniprot.org/uniprot/P59594",
                "http://www.uniprot.org/uniprot/P0DTC2"
            ],
            "Protein Existence": "Protein level",
            "Biological Activity": [
                "Antimicrobial",
                "Antiviral(SARS-CoV-2)"
            ],
            "Target Organism": "[Ref.32376627]Virus:SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.025 ± 0.002 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.08±0.017 µM);SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=0.251 ± 0.118 µM);Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",
            "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
            "Cytotoxicity": "No cytotoxicity information found in the reference(s) presented",
            "Binding Target": "liposomes",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Chol",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C174H299N49O59",
            "Mass": 4021.53,
            "PI": 4.66,
            "Net Charge": -2,
            "Hydrophobicity": -0.19,
            "Half Life": "Mammalian:20 hourYeast:30 minE.coli:>10 hour",
            "Mechanism of action": "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",
            "Literature": [
                {
                    "Title": "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",
                    "Pubmed ID": "32376627",
                    "Reference": "J Virol. 2020 Jul 1;94(14)e00635-20.",
                    "Author": "Zhu Y, Yu D, Yan H, Chong H, He Y.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=32376627"
                }
            ],
            "Frequent Amino Acids": "ILN",
            "Absent Amino Acids": "CFHMOPTUWY",
            "Basic Residues": 4,
            "Acidic Residues": 6,
            "Hydrophobic Residues": 15,
            "Polar Residues": 19,
            "Positive Residues": 4,
            "Negative Residues": 6,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_13518",
                    "Similarity": 1.0,
                    "Sequence": "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL"
                },
                {
                    "SPADE_ID": "SPADE_UN_13521",
                    "Similarity": 1.0,
                    "Sequence": "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL"
                },
                {
                    "SPADE_ID": "SPADE_UN_13554",
                    "Similarity": 1.0,
                    "Sequence": "EISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL"
                }
            ]
        }
    }
}